No Data
No Data
China Antibody-B (03681) released annual results, achieving revenue of 1.3665 million yuan, and all businesses achieved expected performance
China Antibody-B (03681) announced its annual results for the year ended December 31, 2023, and the group achieved revenue...
SINOMAB BIO-B: ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED 31 DECEMBER 2023; CHANGE IN USE OF PROCEEDS; PROPOSED AMENDMENT TO THE 2022 SHARE OPTION SCHEME; AND PROPOSED REFRESHMENT OF SCHEME MANDATE LIMIT AND SERVICE PROVIDER SUBLIMIT
China Antibody-B (03681.HK) plans to hold a board meeting on March 25 to consider and approve annual results
Gelonghui March 12 | China Antibody-B (03681.HK) announced that a board meeting will be held on March 25, 2024 (Monday) to consider and approve the Group's annual results and announcements for the year ended December 31, 2023, and to deal with other matters.
SINOMAB BIO-B: DATE OF BOARD MEETING
China Antibody-B (03681): Wang Shanchun appointed as Executive Director
China Antibody-B (03681) announced that Wang Shanchun has been appointed as the company's executive director since February 2024...
China Antibody-B completed the issuance of a total of 8.512,600 subscribed shares
China Antibody-B (03681) announced that since the prerequisites contained in the remaining two subscription agreements have been met, the two subscription agreements were completed on January 31, 2024 in accordance with the terms and conditions of the relevant subscription agreements. A total of 8,512,600 shares, which is equivalent to approximately 0.79% of the company's issued share capital immediately before completing the remaining two subscription agreements; and approximately 0.78% of the company's issued share capital expanded by issuing subscription shares, which have been issued to subscribers at a subscription price of HK$1.29 per subscribed share. The net proceeds from the subscription process will be approximately HK$10.9813 million as per the announcement
No Data